The Quantellect read.As of Nov 19, 2026, 3 active firms cover Treace Medical Concepts Inc: 1 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets span $5.00 to $7.00, a moderate spread. The average target of $6.00 sits 32% above the current $4.53. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.27 next quarter toward $-0.76 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Neutral
Strong Buy00%
Buy133%
Neutral267%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.00
+32.5% upside
Average target across 2 active firms as of Nov 19, 2026 vs $4.53 current
Highest Target$7.00
Average Target$6.00
Lowest Target$5.00
Detailed analyst forecasts for TMCI
Showing 1–2 of 2 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 1 of 3 active firms rate TMCI a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TMCI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.27
Range $-0.29 – $-0.26 · 4 analysts · -4% YoY
Next period, 4 analysts expect Treace Medical Concepts Inc to earn $-0.27 a share (range $-0.29 – $-0.26), versus $-0.28 a year earlier. Full-year consensus is $-0.81, growing to $-0.76 the year after.
REVENUE · NEXT QUARTER
$50.6M
Range $50.0M – $51.0M · 4 analysts · +7% YoY
Revenue is expected to reach $50.6M (range $50.0M – $51.0M), +7.2% year-over-year. Full-year consensus is $208.0M, rising to $220.7M next year.
Top analysts covering Treace Medical Concepts Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TMCI.
#1
Ryan Zimmerman
BTIG · Rank #212
Neutral
No targeton TMCI
Overall win rate
37%
+ Follow
#2
Richard Newitter
Truist Securities · Rank #532
Neutral
$5.00+10.4% to target
Overall win rate
30%
+ Follow
#3
BH
Ben Haynor
Lake Street
Buy
$7.00+54.5% to target
Coverage
—
+ Follow
#4
LL
Lilia-Celine (Lily) Lozada
J.P. Morgan
Sell
$5.00+10.4% to target
Coverage
—
+ Follow
#5
Danielle Antalffy
UBS
Neutral
$2.25-50.3% to target
Coverage
—
+ Follow
TMCI stock forecast FAQ
What is TMCI's average 12-month price target?+
The 2 active firms with a live target average $6.00 for Treace Medical Concepts Inc over the next 12 months, ranging from a $7.00 high to a $5.00 low, as of Nov 19, 2026.
Is TMCI stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 3 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for TMCI?+
The Street-high target is $7.00 (Lake Street), and the Street-low is $5.00 (Truist Securities). The average of all 2 active-firm targets is $6.00.
How many active Wall Street firms cover TMCI?+
3 active firms have a recognized rating on Treace Medical Concepts Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TMCI?+
Among analysts who currently cover TMCI, Ryan Zimmerman of BTIG has the strongest overall Quantellect track record (Rank #212). Their current call is Neutral.
What is Treace Medical Concepts Inc's projected EPS for next quarter?+
The consensus estimate is $-0.27 per share (range $-0.29 – $-0.26) across 4 analysts. Full-year EPS is projected at $-0.81, rising to $-0.76 the following year.
How much revenue is Treace Medical Concepts Inc expected to report next quarter?+
Consensus revenue is $50.6M (range $50.0M – $51.0M). Full-year revenue is projected at $208.0M, growing to $220.7M next year.
Have analysts been upgrading or downgrading TMCI lately?+
As of Nov 19, 2026, 1 of 3 active firms rate TMCI a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TMCI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.